SSGJ-613
As of the edition of 20 October 2026, SSGJ-613 is a drug known only by a code name: in active development; acts on IL1B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nutrition and metabolism; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL1B | Interleukin-1 beta | P01584 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sunshine Guojian Pharmaceutical | Lead sponsor of trials | 2021 to now |